切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (04) : 159 -162. doi: 10.3877/cma.j.issn.2095-3216.2016.04.004

所属专题: 文献

专家论坛

终末期糖尿病肾病患者透析方式的选择
关天俊1()   
  1. 1. 361004 厦门大学附属中山医院肾内科
  • 收稿日期:2016-04-21 出版日期:2016-08-28
  • 通信作者: 关天俊
  • 基金资助:
    2015年福建省自然科学基金(2015J01532)

Choice of dialysis modality for patients with end-stage diabetic nephropathy

Tianjun Guan1,()   

  1. 1. Department of Nephrology, Zhongshan Hospital Affiliated to Xiamen University School of Medicine, Xiamen 361004, China
  • Received:2016-04-21 Published:2016-08-28
  • Corresponding author: Tianjun Guan
  • About author:
    Corresponding author: Guan Tianjun, Email:
引用本文:

关天俊. 终末期糖尿病肾病患者透析方式的选择[J]. 中华肾病研究电子杂志, 2016, 05(04): 159-162.

Tianjun Guan. Choice of dialysis modality for patients with end-stage diabetic nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(04): 159-162.

糖尿病肾病(DN)是导致终末期肾脏病的重要病因之一。终末期DN患者可选择的透析方式包括血液透析和腹膜透析,而具体选择何种透析方式,需要综合考虑共存疾病、家庭情况、患者的独立性与积极性、耐受容量转移的能力、血管条件和/或腹部的状态、感染风险及感染史等。

Diabetic nephropathy (DN) is one of the major causes of end-stage renal disease (ESRD). Patients with end-stage DN can choose dialysis modality of either hemodialysis (HD) or peritoneal dialysis (PD), depending upon the following factors: comorbid disease, home conditions, independence and motivation of a patient, ability to tolerate volume shift, status of the vasculature and/or abdomen, risk and history of infection, and so on.

[1]
Xu Y,Wang L,He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959.
[2]
Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes- United States and Puerto Rico, 1996-2007[J]. MMWR Morb Mortal Wkly Rep, 2010, 59(42): 1361-1366.
[3]
Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006[J]. Am J Kidney Dis, 2006, 48(Suppl 1): S2-S90.
[4]
US Renal Data System. USRDS 2014 annual data report (2014): end-stage renal disease in the United States[CD/OL].

URL    
[5]
刘莉,王梅,李雪梅, 等. 北京市血液透析患者的透析时机的变迁[J]. 中国血液净化, 2014, 13(12): 855-859.
[6]
Cooper BA,Branley P,Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis[J]. N Engl J Med, 2010, 363(7): 609-619.
[7]
Lameire NH. The impact of residual renal function on the adequacy of peritoneal dialysis[J]. Contrib Nephrol, 1998, 124: 76-93.
[8]
van Olden RW,van Acker BA,Koomen GC, et al. Contribution of tubular anion and cation secretion to residual renal function in chronic dialysis patients[J]. Clin Nephrol, 1998, 49(3): 167-172.
[9]
Moist Lm,Vonesh EF,Gotcg F, et al. Predictors of loss of residual renal function among new dialysis patients[J]. J Am Soc Nephrol, 2000, 11(3): 556-564.
[10]
Jansen MA,Hart AA,Korevaar JC, et a1. Predictors of the rate of decline of residual renal function in incident dialysis patients[J]. Kidney Int, 2002, 62(3): 1046-1053.
[11]
Canada USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes[J]. J Am Soc Nephrol, 1996, 7(2): 198-207.
[12]
Glorieux G,Vanholder R. New uremic toxins-which solutes should be removed?[J]. Contrib Nephrol, 2011, 168: 117-128.
[13]
Saran R,Li Y,Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States[J]. Am J Kidney Dis, 2015, 66(1 Suppl 1): S1-S305.
[14]
Hou F,Jiang J,Chen J, et a1. China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis[J]. BMC Nephrol, 2012, 13: 94.
[15]
Morioka T,Emoto M,Tabata T, et a1. Glycemic control is a predictor of survival for diabetic patients on hemodialysis[J]. Diabetes Care, 2001, 24(5): 909-913.
[16]
Simic-Ogrizovic S,Backus G,Mayer A, et al. The influence of different glucose concentrations in haemodialysis solutions on metabolism and blood pressure stability in diabetic patients[J]. Int J Artif Organs, 2001, 24: 863-869.
[17]
Salamon K,Woods J,Paul E, et al. Peritoneal dialysis patients have higher prevalence of gastrointestinal symptoms than hemodialysis patients[J]. J Ren Nutr, 2013, 23(2): 114-118.
[18]
Wang T,Heimbürger O,Bergström J, et al. Nutritional problems in peritoneal dialysis: an overview[J]. Perit Dial Int, 1999, 19 Suppl 2: S297-S303.
[19]
Cianciaruso B,Brunori G,Kopple JD, et al. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients[J]. Am J Kidney Dis, 1995, 26(3): 475-486.
[20]
Bossola M,Muscaritoli M,Tazza L, et al. Malnutrition in hemodialysis patients: What therapy?[J]. Am J Kidney Dis, 2005, 46(3): 371-386.
[21]
Chung S,Koh ES,Shin SJ, et al. Malnutrition in patients with chronic kidney disease[J]. Open J Intern Med, 2012, 2: 89-99.
[22]
Pulliam J,Li NC,Maddux F, et al. First-year outcomes of incident peritoneal dialysis patients in the United States[J]. Am J Kidney Dis, 2014, 64(5): 761-769.
[23]
Collins AJ,Foley RN,Herzog C, et al. US Renal Data System 2012 Annual Data Report[J]. Am J Kidney Dis, 2013, 61(1 Suppl 1): e1-e476.
[24]
Miskulin DC,Meyer KB,Athienites NV, et al. Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study[J]. Am J Kidney Dis, 2002, 39(2): 324-336.
[25]
McDonald SP,Marshall MR,Johnson DW. Polkinghorne KR. Relationship between dialysis modality and mortality[J]. J Am Soc Nephrol, 2009, 20(1): 155-163.
[26]
Yeates K,Zhu N,Vonesh E, et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada[J]. Nephrol Dial Transplant, 2012, 27(9): 3568-3575.
[27]
US Renal Data System. USRDS 2009 annual data report (2009): Atlas of chronic kidney disease and end-stage renal disease in the United States[CD/OL].

URL    
[28]
Ekart R,Hojs R. Obese and diabetic patients with end-stage renal disease: Peritoneal dialysis or hemodialysis?[J]. Eur J Intern Med, 2016, 32: 1-6.
[1] 吴红兵, 王志维, 李罗成, 任宗力, 胡俊霞, 宋鹏, 阮永乐. 心肾联合移植治疗终末期心肾疾病二例经验总结[J]. 中华移植杂志(电子版), 2022, 16(06): 369-372.
[2] 程莉, 章晓良. 血尿酸和胱抑素C与糖尿病视网膜病变患者合并糖尿病肾病的关系及影响因素[J]. 中华肾病研究电子杂志, 2023, 12(04): 194-199.
[3] 吴震宇, 胡亚芬, 董晓芬, 马远方. 血清CTGF、TGF-β1、MMP2水平对糖尿病肾病肾间质纤维化的预测分析[J]. 中华肾病研究电子杂志, 2022, 11(06): 332-337.
[4] 雷建东, 吴林军, 季沙, 蒋志敏. 糖尿病肾病维持性血液透析患者低血糖预测模型及评分量表的建立[J]. 中华肾病研究电子杂志, 2022, 11(06): 311-317.
[5] 徐新丽, 于小勇. 表观遗传——中医药治疗糖尿病肾病新视角[J]. 中华肾病研究电子杂志, 2022, 11(05): 276-280.
[6] 李子扬, 包继文, 尧欢珍, 张敏芳, 顾乐怡, 倪兆慧, 王玲. 低剂量免疫抑制剂治疗轻中症ANCA相关性肾血管炎的效果和肾脏预后分析[J]. 中华肾病研究电子杂志, 2022, 11(05): 241-248.
[7] 贾英民, 张术姣, 耿运玲, 曹梓静, 王耀献, 吕仁和, 刘玉宁, 刘伟敬. 蝉花菌丝联合海昆肾喜胶囊对糖尿病肾小管上皮细胞自噬-溶酶体通路的影响[J]. 中华肾病研究电子杂志, 2022, 11(04): 212-218.
[8] 王婷燕, 申颖娇, 王爱平, 姚明凤. 递增式血液透析对终末期肾病患者肾功能、微炎症及死亡率的影响[J]. 中华肾病研究电子杂志, 2022, 11(04): 197-201.
[9] 张赟辉, 罗军, 刘栗丽, 汪宏, 耿克明. 腹膜透析与血液透析对老年终末期肾病患者营养状况及炎症反应的影响[J]. 中华临床医师杂志(电子版), 2023, 17(04): 419-423.
[10] 朱艺平, 陈一平, 赵艳英, 陆玮玮, 牙侯军, 苏复霞. 二十味沉香丸调控糖尿病肾病大鼠肠道菌群益生菌构成的机制研究[J]. 中华临床医师杂志(电子版), 2022, 16(06): 572-578.
[11] 刘倩影, 刘雪彦, 周佩如, 胡申玲, 叶倩呈, 黄洁微. 糖尿病肾病患者血液透析期间低血糖管理的证据总结[J]. 中华肥胖与代谢病电子杂志, 2023, 09(01): 22-27.
[12] 王慧卿, 李银玉, 张继敏, 黄正丽, 孙喜明, 薛少青, 焦爱富, 赵慧媛, 尉杰忠. 血清adipsin及皮下脂肪面积与早期糖尿病肾病的相关性分析[J]. 中华肥胖与代谢病电子杂志, 2022, 08(04): 256-262.
[13] 沈地, 权莉, 梁存禹, 孟齐, 艾比拜·玉素甫. 葡萄糖目标范围内时间与2型糖尿病患者尿微量白蛋白水平的相关性研究[J]. 中华肥胖与代谢病电子杂志, 2022, 08(04): 249-255.
[14] 何圣清, 袁唯唯, 孟莞瑞, 符青松, 郑晓斌, 武红梅. 达格列净联合二甲双胍治疗对早期2型糖尿病肾病患者肾小管功能和血清Klotho的影响[J]. 中华肥胖与代谢病电子杂志, 2022, 08(04): 236-242.
[15] 白明悦, 杨淑娜, 胡红梅, 胡文立. 透析患者脑小血管病患病情况的研究现状及其机制探讨[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 505-509.
阅读次数
全文


摘要